Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-VISTA-IgG1
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-VISTA-IgG1 is an experimental monoclonal antibody targeting V-domain Ig suppressor of T cell activation (VISTA), also known as PD-1H. Developed by Boehringer Ingelheim, this antibody is engineered with a human IgG1 isotype to leverage Fc-gamma-receptor (FcγR) interactions for immune stimulation. Unlike its IgG4 counterpart, the IgG1 variant is capable of activating resting immune cells, such as upregulating HLA-DR on myeloid cells, in addition to augmenting ongoing immune responses. Its activity is strictly dependent on Fc-receptor binding, suggesting a mechanism that involves cross-linking or effector cell engagement to overcome VISTA-mediated immunosuppression in the tumor microenvironment. Research has explored its potential in treating hematological malignancies like acute myeloid leukemia (AML) and other oncological indications.
- Other names
- VISTA-IgG1 isotype antibodyVISTA-IgG-1 isotype antibodyVISTA-IgG 1 isotype antibody
02
Targets
VISTAFCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGR1A (High affinity immunoglobulin gamma fc receptor I)
Beyond the preview
Go deeper on anti-VISTA-IgG1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-VISTA-IgG1.